Emerging as a promising breakthrough in the battle against obesity, the drug is generating considerable interest . It combines effects of two known GLP-1 receptor agonists, liraglutide, and an unique glucose-dependent incretin component. Initial clinical findings have demonstrated substantial weight loss in individuals with obesity , potentially of